Role of neurotrophins and lectins in prevention of ototoxicity.
Degeneration of hair cells (HC) and/or spiral ganglion neurons (SGN) is a major cause of hearing loss. Postnatal rat cochlear explant cultures are used to study the toxic actions of different classes of ototoxins and to identify molecules that can protect SGN and HC from ototoxic damage. Various ototoxins induce differential damage to HC and/or SGN. While gentamicin preferentially causes HC death, sodium salicylate selectively induces degeneration of SGN. In contrast, cisplatin results in destruction of both SGN and HC. Specific neurotrophins, including NT-4/5, BDNF, and NT-3, greatly protect SGN from all three types of ototoxins. In contrast, NGF and other growth factors have no effect. Of the 51 compounds examined, only concanavalin A (Con A), a lectin molecule, significantly protects HC from gentamicin. A dose-dependent study of Con A shows that maximal protection occurred at 100 nM. Further experiments indicates that preincubation of Con A with gentamicin does not form a complex, and coaddition of Con A and gentamicin to bacterial cultures, such as E. Coli cultures, does not interfere with the antibiotic activity of gentamicin. When the other 21 lectins are examined, Erythrina cristagalli lectin and Detura stramonium lectin also show activity similar to Con A. These findings may help elucidate the mechanisms of ototoxins and suggest that specific neurotrophins and lectins may be of therapeutic value in the prevention of ototoxin-induced hearing loss.
Gao
W Q
WQ
Department of Neuroscience, Genentech, Inc., South San Francisco, California 94080, USA. gao@gene.com
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology* / Q000627:therapeutic use; D003638:Deafness / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D005839:Gentamicins / Q000009:adverse effects; D006198:Hair Cells, Auditory / Q000187:drug effects* / Q000502:physiology; D037102:Lectins / Q000494:pharmacology* / Q000627:therapeutic use; D009414:Nerve Growth Factors / Q000494:pharmacology / Q000627:therapeutic use; D009416:Nerve Regeneration / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D013136:Spiral Ganglion / Q000187:drug effects* / Q000502:physiology
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D037102:Lectins; D009414:Nerve Growth Factors; D003208:Concanavalin A